Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 1×
“8) (52) to human reference genome (hg19) along with the gene annotation data downloaded from Illumina’s iGenomes (http://support.”
MethodMass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 2×
“As peptides eluted they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).”
MethodNGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 7×
“In many cases, ubiquitin is added to substrates by cullinRING ligases (CRLs), which are multisubunit ubiquitin ligases (23).”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“This is the same mechanism by which the plant hormone auxin acts like “molecular glue” to enhance an interaction between the E3 ubiquitin ligase receptor TIR1 and its substrates (43).”
Background
Cited by
Items 401–500 of 786
Ding, B., Hu, J., Shou, B., Li, J., Yang, B., Cao, J., & Zhu, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00949 · Cited by 14
Genetic and compound screens uncover factors modulating cancer cell response to indisulam
Pogacar, Z., Groot, K., Jochems, F., Dias, M. D. S., Mulero‐Sánchez, A., Morris, B., Roosen, M. M., Wardak, L., Conti, G. D., Velds, A., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101348 · Cited by 14
Dong, X., Han, Y., Zhang, E., Wang, Y., Zhang, P., Wang, C., Zhong, L., & Li, Q. (2021) · Aging · doi:10.18632/aging.202823 · Cited by 14
Tong, J., ZHANG, X., Luo, D., & Bian, S. (2021) · Chinese Journal of Analytical Chemistry · doi:10.1016/j.cjac.2021.09.006 · Cited by 13
Small-Molecule Degraders of Cyclin-Dependent Kinase Protein: A Review
Yu, B., Du, Z., Zhang, Y., Li, Z., & Bian, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0154 · Cited by 15
RNA Regulators in Leukemia and Lymphoma
Prieto, C., & Kharas, M. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034967 · Cited by 14
Emerging mechanisms of targeted protein degradation by molecular glues
Frere, G. A., de Araujo, E. D., & Gunning, P. T. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.01.001 · Cited by 14
Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs
Winter, G. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00191 · Cited by 13
MolGlueDB: an online database of molecular glues
Wang, X., Zhuang, Z., Zhang, C., Zhang, B., Zhan, W., Wang, Y., Liu, Z., Yuan, S., Niu, W., He, Q., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf811 · Cited by 22
Embree, C. M., Paul, D., Stephanou, A., & Singh, G. (2025) · RNA Biology · doi:10.1080/15476286.2025.2552517 · Cited by 17
Pokhrel, S., Kraemer, B. R., Lee, L., Samardzic, K., & Mochly‐Rosen, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251426 · Cited by 12
Tan, Y., Liu, B., Han, Y., Zhang, Y., Zhang, H., & Zhao, J. (2020) · Chemistry - An Asian Journal · doi:10.1002/asia.202000916 · Cited by 12
Polymer Matrix-Based Carbon Nanocomposites for Neural Tissue Engineering
Ghosh, S., Roy, P., & Lahiri, D. (2021) · Transactions of Indian National Academy of Engineering · doi:10.1007/s41403-021-00291-2 · Cited by 12
Rothweiler, E. M., Brennan, P. E., & Huber, K. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0396 · Cited by 13
Challenges in Therapeutically Targeting the RNA‐Recognition Motif
Schmeing, S., & Hart, P. '. (2024) · WIREs RNA · doi:10.1002/wrna.1877 · Cited by 11
Keun, H. C., & Nijhuis, A. M. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.012 · Cited by 11
Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies
Bauer, M., Schöbel, C.-M., Wickenhauser, C., Seliger, B., & Jasinski‐Bergner, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386993 · Cited by 11
Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer
Bi, R., Chen, L., Huang, M., Qiao, Z., Li, Z., Fan, G., & Wang, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189221 · Cited by 11
Luo, Y., Liu, C., Luo, Y., Zhang, X., Li, J., Hu, C.-J., & Yang, S. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01085-y · Cited by 13
RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B/β-catenin Pathway
Liu, N., Zhang, J., Chen, W., Ma, W., & Wu, T. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101404 · Cited by 12
RNA splicing as a therapeutic target in myelodysplastic syndromes
Tseng, C.-C., & Obeng, E. A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.005 · Cited by 14
Therapeutic targeting of RNA splicing in myelodysplasia
Kim, Y. J., & Abdel-Wahab, O. I. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.007 · Cited by 11
Mainolfi, N., & Rasmusson, T. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.005 · Cited by 12
Chen, M., Wijethunge, B. D. I. K., Zhou, S.-M., Yang, J.-F., Dai, L., Wang, S., Chen, C., Fu, L.-J., Zhang, J., Hao, G., et al. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b02086 · Cited by 11
Spatial variability of low frequency brain signal differentiates brain states
Wang, Y., Ao, Y., Yang, Q., Liu, Y., Ouyang, Y., Jing, X., Pang, Y., Cui, Q., & Chen, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242330 · Cited by 11
Small-molecule modulators of protein–RNA interactions
Byun, W. G., Lim, D., & Park, S. B. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102149 · Cited by 13
Pharmacological Modulation of Transcriptional Coregulators in Cancer
Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 12
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Darling, S., Bajrami, I., & West, S. C. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2564068 · Cited by 9
“Several targets, already engaged by glue degraders in the clinic, show promise as pan-cancer therapies. given their crucial roles in several essential cellular processes RBM39 and gSPt1 represent attractive candidates for a pan-cancer approach. custom celMoDs targeting gSPt1 have already demonstrated potential across…”
InfluentialChen, Z., Chi, G., Balo, T., Chen, X., Montes, B. R., Clifford, S. C., D’Angiolella, V., Szabo, T., Kiss, A., Novak, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58350-z · Cited by 10
Figg, J., Barajas, J. M., & Obeng, E. A. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000632 · Cited by 10
YAP/TAZ interacts with RBM39 to confer resistance against indisulam
Ando, T., Okamoto, K., Ueda, Y., Kataoka, N., Shintani, T., Yanamoto, S., Miyauchi, M., & Kajiya, M. (2024) · Oncogenesis · doi:10.1038/s41389-024-00527-0 · Cited by 13
Jang, J., Kim, J.-Y., & Lee, T. J. (2024) · Genes & Genomics · doi:10.1007/s13258-024-01565-z · Cited by 11
Self-citationAberrant pre-mRNA processing in cancer
Biswas, J., Boussi, L. S., Stein, E. M., & Abdel-Wahab, O. I. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230891 · Cited by 10
Targeted protein and protein-condensate degradation in plant science research and crop breeding
Niu, R., Luo, M., Wen, Q., Xiong, Y., Dang, H., & Xu, G. (2025) · Molecular Plant · doi:10.1016/j.molp.2025.06.013 · Cited by 10
Gui, W., Goss, A., & Kodadek, T. J. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07307 · Cited by 12
Rational discovery of molecular glue degraders based on block chemistry
Wei, J., Feng, W., Chen, Q., Li, Q., & Chen, Z. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104480 · Cited by 12
Fan, C., Wang, X., Ling, T., Yang, Y., & Zhao, H. (2023) · RNA Biology · doi:10.1080/15476286.2023.2231708 · Cited by 10
Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges
Jia, Q., Sun, X., Li, H., Guo, J., Niu, K., Chan, K. M., Bernards, R., Qin, W., & Jin, H. (2024) · Gut · doi:10.1136/gutjnl-2024-333127 · Cited by 11
Hülskamp, M. D., Kronenberg, D., & Stange, R. (2021) · BMC Cancer · doi:10.1186/s12885-021-08301-w · Cited by 11
Lorenzi, L., Lonardi, S., Vairo, D., Bernardelli, A., Tomaselli, M., Bugatti, M., Licini, S., Arisi, M., Cerroni, L., Tucci, A., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001747 · Cited by 10
Controllable transformation of indoles using iodine( iii ) reagent
Jian, Y., Peng, L., Li, X., Shao, H., & Ma, X. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob01951e · Cited by 10
Dlamini, Z., Shoba, B., & Hull, R. (2020) · PubMed · Cited by 10
Kim, S. A., Jo, S.-H., Cho, J. H., Yu, M. Y., Shin, H., Kim, J., Park, S. G., Park, B. C., Kim, S., & Kim, J. (2020) · Molecules and Cells · doi:10.14348/molcells.2020.0122 · Cited by 11
Self-citationSynthesis of N-substituted sulfonamides containing perhalopyridine moiety as bio-active candidates
Hosseini, R., Ranjbar‐Karimi, R., & Mohammadiannejad, K. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109507 · Cited by 10
Characterisation of high throughput screening outputs for small molecule degrader discovery
Bell, L. E., Bardelle, C., Packer, M. J., Kastl, J., Holdgate, G. A., & Davies, G. (2024) · SLAS Discovery · doi:10.1016/j.slasd.2024.100162 · Cited by 9
Zhao, C., Wang, H., Zhan, W., Lv, X., & Ma, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00079 · Cited by 9
Lu, C., Li, J., Li, D., Wang, Y., Jiang, X., Ma, J., & Xu, G. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01431-4 · Cited by 9
Alternative splicing in aging and aging-related diseases: From pathogenesis to therapy
Han, M., Han, P., Wang, Z., Kong, L., Xu, Q., Liu, Q., & Sun, Y. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108887 · Cited by 9
Zhang, T., Wang, S., Zhou, Y., Jiao, Z., Lu, K., Liu, X., Li, H., Jiang, W., & Zhang, X. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3002846 · Cited by 10
Opportunities in proximity modulation: Bridging academia and industry
Đikić, I., Mayor‐Ruiz, C., Winter, G. E., Koch, K., Ciulli, A., & Thomä, N. H. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.07.018 · Cited by 11
Drugging the undruggable: Chemical and biological insights into molecular glues in the pipeline
Metwally, K. A., Yahya, G., & Abo-Dya, N. E. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118132 · Cited by 10
Nukaga, S., Shiraishi, K., Hamabe, K., Mochizuki, A., Hamaguchi, Y., Ogawa, E., Le, N. T., Shimada, Y., Ono, H., Nishinakamura, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64821-0 · Cited by 9
Targeting strategies for modulating pre-mRNA splicing with small molecules: Recent advances
Barraza, S. J., Bhattacharyya, A., Trotta, C. R., & Woll, M. G. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103431 · Cited by 9
Nguyen, T. P., Fang, M., Kim, J., Wang, B., Lin, E., Khivansara, V., Barrows, N., Rivera‐Cancel, G., Goralski, M., Cervantes, C., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.017 · Cited by 10
Self-citationComprehensive characterization of patient-derived xenograft models of pediatric leukemia
Rogojina, A. T., Klesse, L. J., Butler, E. B., Kim, J., Zhang, H., Xiao, X., Guo, L., Zhou, Q., Hartshorne, T., Garcia, D. K., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108171 · Cited by 9
Self-citationZhang, Q., Zhang, Y., Zhang, S., Zeng, Y., He, Z., Yang, K., Luo, J., Guo, H., & Chi, B. (2024) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2024.125652 · Cited by 9
Alternative Splicing in Myeloid Malignancies
Gurnari, C., Pagliuca, S., & Visconte, V. (2021) · Biomedicines · doi:10.3390/biomedicines9121844 · Cited by 9
Li, J., Song, Y., Wang, Y., & Zhang, H. (2019) · Dalton Transactions · doi:10.1039/c9dt03663f · Cited by 9
Shi, Y., Feng, D., Zhou, J., Liu, L., Li, X., Yuan, Z., Wu, J., & Yao, H. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.010 · Cited by 10
Jin, Q., Harris, E. J., Myers, J., Mehmood, R., Cotton, A., Shirnekhi, H. K., Baggett, D. W., Wen, J. Q., Schild, A. B., Bhansali, R. S., et al. (2024) · Blood · doi:10.1182/blood.2024024281 · Cited by 9
Zhang, B., Zhou, Y., Xu, X., Xu, G., Wu, Z., Wu, Q., Zeng, Q., Yang, J., Lv, T., & Yang, J. (2025) · Oncogene · doi:10.1038/s41388-025-03327-x · Cited by 10
Lead discovery and chemical biology approaches targeting the ubiquitin proteasome system
Akinjiyan, F. A., Carbonneau, S., & Ross, N. T. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.058 · Cited by 8
Five Circular RNAs in Metabolism Pathways Related to Prostate Cancer
Zhang, L., Zhang, W., Li, H., Tang, X., Xu, S., Wu, M. Y., Wan, L., Su, F., & Zhang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.636419 · Cited by 8
Ciulli, A., & Hsia, O. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch9 · Cited by 9
The Antagonist Effect of Nitrogen Lone Pair: 3JHFversus5JHF
Barbosa, T. M., Viesser, R. V., Martins, L. G., Rittner, R., & Tormena, C. F. (2018) · ChemPhysChem · doi:10.1002/cphc.201800073 · Cited by 8
Tange, N., Hayakawa, F., Yasuda, T., Odaira, K., Yamamoto, H., Hirano, D., Sakai, T., Terakura, S., Tsuzuki, S., & Kiyoi, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110330 · Cited by 8
Jammal, N., Rausch, C. R., Kadia, T. M., & Pemmaraju, N. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1847272 · Cited by 9
RNA-binding proteins as drivers of AML and novel therapeutic targets
Qin, T., Cheng, Y., & Wang, X. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.2008381 · Cited by 8
Hermawan, A., & Putri, H. (2020) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-020-00028-2 · Cited by 8
Yu, H. H., Reitsma, J. M., Sweredoski, M. J., Moradian, A., Hess, S. Y., & Deshaies, R. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/595389 · Cited by 8
Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches
Miao, Q., Kadam, V. D., Mukherjee, A., Tan, Z., & Teng, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01209 · Cited by 7
GSPT1 degraders: research progress, development strategies and challenges
Liu, C., Peng, H., Chen, P., Li, Y., Deng, Z., Li, S., Yang, T., Liu, P., Wang, Z., & Liu, L. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118390 · Cited by 7
Mechanisms that matter: unbiased cellular screening for degraders
Burston, H. E., Rosethorne, E. M., Cavallo, F., Jordan, A. M., Baruah, P. S., Swift, D., & Hjerpe, R. (2025) · npj Drug Discovery. · doi:10.1038/s44386-025-00028-z · Cited by 8
Molecular glues: A new path to the world of the unattainable
Khaledian, M., Sheikh, H., Babaei, F., Divsalar, A., Gharshasbi, M., Ottmann, C., Haertlé, T., Saboury, A. A., & Rasouli, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148861 · Cited by 8
Regulation of RNA-binding proteins by small biomolecules
Miao, W., Porter, D. F., Lopez-Pajares, V., & Khavari, P. A. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00914-4 · Cited by 8
Molecular Glue Degraders: From Serendipity to Hunting and Design
Nieto‐Barrado, L., Domostegui, A., & Mayor‐Ruiz, C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch6 · Cited by 10
Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment
Tang, W., Xu, J., & Xu, C. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216081 · Cited by 7
Targeting splicing for hematological malignancies therapy
Szelest, M., & Giannopoulos, K. (2024) · BMC Genomics · doi:10.1186/s12864-024-10975-y · Cited by 9
Targeting RBM39 suppresses tumor growth and sensitizes osteosarcoma cells to cisplatin
Wang, J., Zheng, L., Chen, W., Zhang, X., Lv, D., Zeng, C., Zhang, C., Zhang, R., Kang, T., & Zhong, L. (2024) · Oncogene · doi:10.1038/s41388-024-03242-7 · Cited by 7
Synthesis of an RBM39 Degrader That Downregulates CEP192 and Induces Disorganized Spindle Structures
Lyu, X., Wang, X., Lin, D., Lu, Y., Wang, C., Yan, Z., Wang, Z., Cheng, Y., Cheng, J., Ren, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00534 · Cited by 7
New radical methods for the potential synthesis of carbon‐13 and carbon‐14 labeled complex products
Maxwell, B. D. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3680 · Cited by 7
Methods to characterize and discover molecular degraders in cells
Lin, Z., & Woo, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00261b · Cited by 7
Song, K., Nimse, S. B., Kim, J., Warkad, S. D., & Kim, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00646 · Cited by 7
Self-citationZhang, Y., & Erb, M. A. (2021) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100011 · Cited by 7
Dou, Z., Zhang, X., Su, W., Zhang, T., Ye, F., Chen, X., Zhao, D., Li, Q., Zhang, H., & Di, C. (2022) · PubMed Central · doi:10.22541/au.166318209.92748997/v1 · Cited by 10
Alternative Splicing as a Modulator of the Interferon-Gamma Pathway
Suri, P., Badalov, A., & Ruggiu, M. (2025) · Cancers · doi:10.3390/cancers17040594 · Cited by 7
Vainauskas, V., Kavaliauskas, P., Grybaitė, B., Petraitis, V., Petraitienė, R., Grigalevičiūtė, R., Prakapaitė, R., Acevedo, W., & Mickevičius, V. (2025) · ChemMedChem · doi:10.1002/cmdc.202500260 · Cited by 6
Yuan, L., Ji, W., Dwyer, B. G., Lu, J., Bian, J. T., Colombo, G. M., Martinez, M. J., Fernández, D., Phillips, N. A., Tang, M. T., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0271 · Cited by 9
Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders
Crowe, C., & Ciulli, A. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00800 · Cited by 6
Quan, Y., Wang, M., Zhang, H., Lü, D., & Ping, H. (2024) · iScience · doi:10.1016/j.isci.2024.111351 · Cited by 6
Jang, J. H., Kim, H.-I., Jun, H., Park, C.-Y., Kim, J., Yeo, M., Kim, H.-C., Shin, Y., Kang, S., Kim, E. H., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116877 · Cited by 7
Self-citationRecent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs
Shen, Y., Wen, W., Chen, L., Zhang, N., Wei, C., & Hu, H. (2025) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70064 · Cited by 7
Tang, S., Cai, L., Wang, Z., Pan, D., Wang, Q., Shen, Y., Zhou, Y. L., & Chen, Q. (2023) · Cancer Innovation · doi:10.1002/cai2.50 · Cited by 7
Wei, B., Ma, J., Guo, H., Zhang, Y., Zhang, W., Chen, W., Guo, D., Wang, Y., & Tang, Y. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105295 · Cited by 6
Synthetic modification of protein surfaces to mediate induced-proximity pharmacology
Jones, L. H. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00388h · Cited by 6
Shamsel‐Din, H. A., & Zaki, E. G. (2020) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-020-07317-z · Cited by 6
Inducible Protein Degradation to Understand Genome Architecture
Tallan, A. M., & Stanton, B. Z. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00306 · Cited by 6
Targeted Protein Degradation: Principles, Strategies, and Applications
He, T., Wen, C., Yang, G., & Yang, X. (2023) · Advanced Biology · doi:10.1002/adbi.202300083 · Cited by 7
Guo, P., Han, Z., Ran, H., Luo, J., Wu, G., & Yuan, R. (2018) · Bulletin of Engineering Geology and the Environment · doi:10.1007/s10064-018-1338-y · Cited by 6
From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
Nagel, Y. A., Britschgi, A., & Ricci, A. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch2 · Cited by 7
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.